Molecular markers of bone turnover: Biochemical, technical and analytical aspects

Osteoporosis International

Volumn 11, Issue SUPPL. 6, 2000, Pages

  Seibel, M J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; GLYCOSIDASE; HYDROXYLYSINE; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; SIALOPROTEIN;

BONE LEVEL; BONE MINERALIZATION; BONE TURNOVER; COLORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; RADIOIMMUNOASSAY; REVIEW; SAMPLING; TECHNIQUE;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REGENERATION; BONE REMODELING; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROXYLYSINE; HYDROXYPROLINE; OSTEOBLASTS; OSTEOCALCIN; PROCOLLAGEN; SIALOGLYCOPROTEINS; SPECIMEN HANDLING;

EID: 0034526233     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980070003     Document Type: Review

References (171)

1. Mechanisms regulating osteoblast proliferation and differentiation
2. Physiology of calcium and phosphate homeostasis
3. Human liver plasma membranes contain an enzyme activity that removes membrane anchor from alkaline phosphatase and converts it to a plasma-like form
4. The human alkaline phosphatases: What we know and what we don't know
5. Sugar-chain heterogeneity of human alkaline phosphatases: Differences between normal and tumour-associated isoenzymes
6. An unusual alkaline phosphatase isoenzyme associated with gastric carcinoma
7. Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone disease
8. Automated differential isoenzyme analysis. II. The fractionation of serum alkaline phosphatase into liver, intestinal, and other components
9. Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis
10. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase
11. Quantifizierung der alkalischen Knochenphosphatase im Serum mittels Präzipitation und Elektrophorese: Methodenvergleich und Referenzwerte
12. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma
13. Lectin affinity electrophoresis of alkaline phosphatase for the differentiation of bone hepatobiliary disease
14. Alkaline phosphatase isoenzymes resolved by electrophoresis on lectin-containing agarose gel
15. A simple electrophoretic method for separating elevated liver and bone alkaline phosphatase isoenzymes in plasma after neuraminidase treatment
16. Assay of alkaline phosphatase isoenzymes by a convenient precipitation and inhibition methodology
17. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: A simplified method and its clinical plausibility
18. Wheat-germ agglutinin method for measuring bone and liver isoenzymes of alkaline phosphatase assessed in postmenopausal osteoporosis
19. Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: Age-dependent reference ranges and changes in liver and bone disease
20. Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity
21. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum
22. Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity
23. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone disease
24. Non-invasive evaluation of bone formation: Measurements of serum alkaline phosphatase, whole body retention of diphosphonate and serum osteocalcin in metabolic bone disorders and thyroid disease
25. Bone alkaline phosphatase as indicator of bone formation
26. Quantitation of human intestinal and liver/bone alkaline phosphatase in serum by rocket electroimmunoassay
27. Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin
28. Clinical usefulness of alkaline phosphatase isoenzyme determinations
29. Clinical assessment of the electrophoretic separation of alkaline phosphatase isoenzymes
30. Carboxylated calcium-binding proteins and vitamin K
31. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
32. Osteocalcin: Genetic and physical mapping of the human gene BGLAP and its potential role in postmenopausal osteoporosis
33. Vitamin K dependent proteins of bone and cartilage
34. Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours
35. Vitamin K-dependent proteins
36. Increased bone formation in osteocalcin-deficient mice
37. Serum bone glaprotein: A specific marker for bone formation in postmenopausal osteoporosis
38. Homologous radioimmunoassay of human osteocalcin
39. Region-specific radioimmunoassay for human gamma-carboxyglutamic acid-containing protein (BGP) in blood of normal subjects
40. Increase in serum bone gamma-carboxyglutamic acid protein with aging in women
41. Determination of osteocalcin in human serum: Results with two kits compared with those by a well-characterized assay
42. Radioimmunoassay for human osteocalcin using an antibody raised against the synthetic human (h37-49) sequence
43. A one step sandwich enzyme immunoassay for gamma-carboxylated osteocalcin using monoclonal antibodies
44. Plasma osteocalcin in man
45. A specific radioimmunoassay for osteocalcin with advantageous species crossreactivity
46. Solid-phase enzyme immunoassay for osteocalcin in human serum or plasma, with use of a monoclonal antibody
47. Development of a new radioimmunossay for human osteocalcin: Evidence for a midmolecule epitope
48. Avidin-biotin enzyme immunoassay of osteocalcin in serum or plasma
49. Sandwich immunoassay for intact human osteocalcin
50. Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin
51. Two-site enzyme immunoassay for measuring intact human osteocalcin in serum
52. Production of monoclonal and polyclonal antibodies against human osteocalcin sequences and development of a two-site ELISA for intact human osteocalcin
53. Two-site assays of bone Gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule
54. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin
55. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
56. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women
57. Serum bone-Gla-protein compared to bone histomorphometry in endocrine diseases
58. Osteocalcin and its message: Relationship to bone histology in magnesium-deprived rats
59. Evidence that free gamma carboxyglutamic acid circulates in serum
60. Effect of acute increase in bone matrix degradation on circulating levels of bone-Gla protein
61. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro
62. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay
63. Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B, D, L, H, and S
64. The cross-reactivities of cathepsin generated bone GLA protein-fragments in different immunoassays
65. A heterogeneity in serum osteocalcin N-terminal fragments in Paget's disease: Comparison with other biochemical indices in pre- and post-menopause
66. Removal of osteoclast bone resorption products by transcytosis
67. Degradaion of bone matrix proteins by osteoclast cathepsins
68. Validation of the bone Gla protein (osteocalcin) assay
69. Bone gla protein (osteocalcin) assay standardization report
70. Commercial assays for serum osteocalcin give clinically discordant result
71. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: A study of sources of variation in assay results
72. Six osteocalcin assays compared
73. Collagen in tendon, ligament, and bone healing: A current review
74. Identification and partial characterization of the non-collagenous amino- and carboxy-terminal extension peptides of cartilage procollagen
75. Procollagen: Biological scission of amino and carboxy extension peptides
76. Purification and characterization of a peptide from the carboxy-terminal region of chick tendon procollagen type I
77. Circulating Cterminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells
78. Biosynthesis of the collagens
79. Radioimmunassay of the carboxyterminal propeptide of human type I procollagen
80. Radioimmunoassay for human procollagen
81. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide
82. Serum markers of type 1 collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry
83. The carboxy-terminal propeptide of type 1 procollagen in serum as a marker of bone formation: The effect of nandrolone decanoate and female sex hormones
84. Procollagen type I carboxyterminal extension propeptide in serum as a marker of collagen biosynthesis in bone
85. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases
86. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery
87. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: Relation to calcium kinetics
88. Hydroxyproline metabolism by the rat kidney: Distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine
89. Urinary excretion of hydroxyproline in health and disease
90. Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis
91. Urinary excretion of hyroxylysine and its glycosides as an index of collagen degradation
92. Intracellular degradation of newly synthesized collagen
93. The biosynthesis of collagen and its disorders
94. Turnover of collagen and its precursors
95. The isolation of identical hydroxylysyl glycosides from hydroxylates of soluble collagen and from human urine
96. High performance liquid chromatography analysis of urinary hydroxylysine glycosides as indicators of collagen turnover
97. Urinary-1-galactosyl-O-hydroxylysine as a marker of collagen turnover in bone
98. The glycosides of hydroxylysine are final products of collagen degradation in humans
99. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism
100. Determination of galactosyl hydroxyysine in urine as a means for the identification of osteoporotic women
101. The comparative performance of urinary bone resorption markers: Galactosyl hydroxylysine, pyridinium crosslinks, hydroxyproline
102. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption
103. The structure of pyridinoline, a collagen crosslink
104. A novel fluor in insoluble collagen: A crosslinking molecule in collagen molecule
105. Fibrillogenesis and maturation of collagens
106. Structure and biosynthesis of collagens
107. Collagen crosslink components in human urine
108. Urinary excretion of pyridinoline crosslinks correiates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis
109. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis
110. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption
111. The Marfan syndrome: A deficiency in chemically stable collagen cross-linking
112. Collagen crosslinking in human bone and articular cartilage
113. Cross-linking in collagen and elastin
114. Pyridinium crosslinks of bone collagen and their location in peptides isolated from rat femur
115. Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease
116. Measurement of biochemical markers of bone resorption
117. Validation of local and systemic markers of bone turnover
118. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography
119. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography
120. Automated on-line solid-phase extraction and high-performance liquid chromatographic analysis of total and free pyridinium crosslinks in serum
121. Direct measurement of free hydroxy-pyridinium crosslinks of collagen in urine as new markers of bone resorption in osteoporosis
122. Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: Sample relationships between 24-h and fasting early morning urine concentrations
123. Immunoassay for urinary pyridinoline: The new marker of bone resorption
124. Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
125. Monoclonal antibody assay for free urinary pyridinium crosslinks
126. Immunoassay of urinary pyridinoline crosslink excretion in normal adults and in Paget's disease
127. Radioimmunoassay for the pyridinoline cross-linked carbxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
128. Bone resorption assay based on a peptide liberated during type I collagen degradation
129. Products of bone collagen metabolism
130. Metastatic bone disease
131. Immunoassay for quantifying type I degradation products in urine evaluated
132. Characterization of urinary degradation products derived from type I collagen: Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region
133. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption
134. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone
135. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease
136. Two new bone resorption assays measuring racemised protein fragments: Measurement of age-modified peptides to assess bone quality
137. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: Assessment of tissue turnover
138. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
139. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
140. Collagen crosslinks in metabolic bone disease
141. Novel serum markers of bone resorption
142. Matrix sialoprotein of developing bone
143. Isolation and characterisation of two sialoproteins present only in bone
144. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone
145. Structure biology of cartilage bone matrix noncollageneous macromolecules
146. Localization of bone sialoprotein (BSP) expression to sites of mineral tissue formation in fetal rat tissue by in situ hybridization
147. Characterization of porine bone sialoprotein: Primary structure and cellular expression
148. Differences in composition of cell-attachment sialoproteins between dentin and bone
149. Expression of bone matrix proteins in human breast cancer: Potential roles in microcalcification formation and in the genesis of bone metastases
150. Expression of bone sialoprotein (BSP) in developing human tissues
151. Identification of a bone sialoprotein receptor in osteosarcoma cells
152. 3 potentiate bone resorption
153. Further characterization of interaction between bone sialoprotein (BSP) and collagen
154. Modulation of crystal formation by bone phosphoproteins: Role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein
155. Increased release of bone sialoprotein into synoial fluid reflects tissue destruction in rheumatoid arthritis
156. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay
157. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease
158. Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissue
159. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function
160. Osteoclastic tartrate-resistant acid phosphatase (Acp 5): Its localization to dendritic cells and diverse murine tissues
161. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies
162. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase
163. Immunoassay of a tartrate-resistant acid phosphatase in serum
164. An optimized continuous-monitoring procedure for semiautoated determination of serum acid phosphatase activity
165. Enzyme immunoassay for tartrate-resistant acid phosphatase
166. Characterization of an assay for human tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption
167. Clinical usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase activity in evaluating bone turnover
168. High bilirubin levels interfere with serum tartrate-resistant acid phosphatase determination: Relevance as a marker of bone resorption in jaundiced patients
169. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population